New cancer clinical trial: Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

Published on: August 31, 2018 at 12:00PM
Conditions:   Leukemia;   Brain Tumor;   Solid Tumor;   Lymphoma
Interventions:   Drug: ALRN-6924;   Drug: Cytarabine
Sponsor:   Dana-Farber Cancer Institute
Not yet recruiting
https://ift.tt/2PqdWl3